Zacks Investment Research downgraded shares of Grifols (NASDAQ:GRFS) from a buy rating to a hold rating in a report issued on Thursday.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
GRFS has been the topic of a number of other reports. Morgan Stanley dropped their price target on shares of Grifols from $23.00 to $22.00 and set an underweight rating on the stock in a research note on Thursday, March 1st. BidaskClub cut shares of Grifols from a hold rating to a sell rating in a research note on Wednesday, February 28th. ValuEngine upgraded shares of Grifols from a hold rating to a buy rating in a research note on Friday, February 2nd. Finally, HSBC upgraded shares of Grifols from a reduce rating to a hold rating in a research note on Wednesday, March 14th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $22.50.
A number of institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. increased its holdings in Grifols by 45.9% during the 4th quarter. Alliancebernstein L.P. now owns 9,063,495 shares of the biotechnology company’s stock worth $207,735,000 after acquiring an additional 2,850,177 shares during the period. Vaughan Nelson Investment Management L.P. increased its holdings in Grifols by 2.6% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 2,901,936 shares of the biotechnology company’s stock worth $66,513,000 after acquiring an additional 72,375 shares during the period. First Trust Advisors LP increased its holdings in Grifols by 3.7% during the 4th quarter. First Trust Advisors LP now owns 1,878,401 shares of the biotechnology company’s stock worth $43,053,000 after acquiring an additional 67,501 shares during the period. Engadine Partners LLP bought a new stake in Grifols during the 4th quarter worth approximately $39,350,000. Finally, Parametric Portfolio Associates LLC increased its holdings in Grifols by 3.5% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 670,604 shares of the biotechnology company’s stock worth $14,680,000 after acquiring an additional 22,782 shares during the period. 22.26% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece of content was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2018/04/20/grifols-grfs-lowered-to-hold-at-zacks-investment-research.html.
Grifols Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.